A number of other equities analysts have also commented on KALV. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a strong-buy rating to a hold rating in a report on Thursday, February 21st. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a report on Monday, February 4th. Finally, Needham & Company LLC began coverage on shares of Kalvista Pharmaceuticals in a report on Wednesday, March 20th. They set a buy rating and a $35.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $30.60.
Shares of NASDAQ:KALV opened at $23.80 on Tuesday. The firm has a market cap of $410.48 million, a PE ratio of -15.56 and a beta of 2.32. Kalvista Pharmaceuticals has a 52 week low of $7.73 and a 52 week high of $34.92.
In related news, major shareholder Life Sciences Fund Iv (Gp) Sv sold 214,198 shares of Kalvista Pharmaceuticals stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $20.55, for a total transaction of $4,401,768.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Svlsf Iv, Llc sold 43,378 shares of Kalvista Pharmaceuticals stock in a transaction on Monday, March 4th. The stock was sold at an average price of $22.91, for a total transaction of $993,789.98. The disclosure for this sale can be found here. Insiders have sold 1,115,719 shares of company stock valued at $29,999,337 in the last three months. 38.40% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. Flinton Capital Management LLC bought a new stake in Kalvista Pharmaceuticals in the fourth quarter valued at $26,000. Barclays PLC increased its stake in Kalvista Pharmaceuticals by 88,319.7% in the fourth quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 62,707 shares in the last quarter. Polar Capital LLP bought a new stake in Kalvista Pharmaceuticals in the fourth quarter valued at $1,558,000. Vanguard Group Inc. increased its stake in Kalvista Pharmaceuticals by 152.4% in the third quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after purchasing an additional 179,092 shares in the last quarter. Finally, Fosun International Ltd bought a new stake in Kalvista Pharmaceuticals in the fourth quarter valued at $2,444,000. 77.44% of the stock is owned by institutional investors and hedge funds.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: Why investors pay attention to retained earnings
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.